.
Cancer treatments are most effective, and patient outcomes are improved, when tumors are detected early.
Imagion Biosystems is developing the MagSense® Systems for early cancer detection using technology that has the potential to surpass conventional imaging methods.
This video illustrates Imagion Biosystems’ MagSense nanoparticle tumor targeting and superparamagnetic relaxometry detection technologies.
The company is preparing to initiate clinical studies of the MagSense System.
Corporate Updates: $3M fundraising led by CPS Capital to be completed in early December Filing of IND for MagSense® HER2 Phase 2 Study Immediate Priority
Imagion Biosystems (ASX: IBX) (Company), is pleased to announce the Company has received $3 million of firm commitments through a highly successful capital raising. The
Open a copy of this presentation deck from our ASX announcement HERE. Video transcript: Mel: Good morning, everyone. Thank you for attending the investor presentation
We’re on a mission to make cancer more detectable.
Imagion Biosystems (IBX) is an innovative medical imaging company that uses bio-safe magnetic nanoparticles to detect cancer and other diseases.
Stay informed about our latest news and developments.
© Imagion Biosystems, Ltd. All Rights Reserved | Privacy Policy | Terms & Conditions | Careers | Corporate Governance